Pacira BioSciences, Inc. (PCRX)

Market Cap	1.01B -13.8%
Revenue (ttm)	726.41M +3.6%
Net Income	7.03M
EPS	0.16
Shares Out	43.02M
PE Ratio	147.37
Forward PE	8.70
Dividend	n/a
Ex-Dividend Date	n/a

Volume	237,583
Open	22.96
Previous Close	23.26
Day's Range	22.96 - 24.10
52-Week Range	18.80 - 27.64
Beta	0.23
Analysts	Strong Buy
Price Target	37.60 (+59.73%)
Earnings Date	Feb 26, 2026

About PCRX

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled dos...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 3, 2011
• Employees: 829
• Stock Exchange: NASDAQ
• Ticker Symbol: PCRX
• Website: https://www.pacira.com

Analyst Summary

According to 5 analysts, the average rating for PCRX stock is "Strong Buy." The 12-month stock price target is $37.6, which is an increase of 59.73% from the latest price.

Price Target

$37.6

(59.73% upside)

Analyst Consensus: Strong Buy